Polymeric lamellar substrate particles for intranasal vaccination

被引:21
作者
Jabbal-Gill, I
Lin, W
Kistner, O
Davis, SS
Illum, L
机构
[1] Drug Delivery & Clin Res Ctr Ltd, Albert Einstein Ctr, W Pharmaceut Serv, Nottingham NG7 2TN, England
[2] Baxter Immuno, Biomed Res Ctr, A-2304 Orth, Austria
关键词
polylactide; PLSP; adjuvants; mucosal; nasal; vaccine;
D O I
10.1016/S0169-409X(01)00173-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In recent years, several strategies have been under investigation to achieve safe and effective immunisation, in terms of new antigens, adjuvants and routes of vaccination. The latter include mucosal sites such as oral, rectal, vaginal and nasal. Biodegradable microparticles produced from polymers such as poly(D,L-lactide) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA) containing encapsulated vaccine antigens have been extensively studied for immunisation. These microparticles allow controlled release of vaccines with the aim to develop as single dose vaccines. However there are concerns regarding the integrity and immunogenicity of the antigen during the encapsulation process when the antigen is exposed to organic solvents, high shear stresses and the exposure of antigen to low pH which is caused by polymer degradation. Polymeric lamellar substrate particles (PLSP) produced by simple precipitation of PLA, form a novel polymeric system for the adsorption of antigens. This procedure avoids PH changes, exposure to organic solvents and hence allows the integrity of the antigen to be retained. The aim of this article is to discuss the factors affecting the characteristics of PLSP and adsorption of antigens onto PLSP and consider their potential as adjuvants for the nasal delivery of protein, peptide or viral vaccines. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:97 / 111
页数:15
相关论文
共 60 条
[1]   PROTEIN ADSORPTION TO POLYMER PARTICLES - ROLE OF SURFACE-PROPERTIES [J].
ABSOLOM, DR ;
ZINGG, W ;
NEUMANN, AW .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1987, 21 (02) :161-171
[2]   Biodegradation and biocompatibility of PLA and PLGA microspheres [J].
Anderson, JM ;
Shive, MS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24
[3]   ADJUVANTS - CURRENT STATUS, CLINICAL PERSPECTIVES AND FUTURE-PROSPECTS (REPRINTED FROM TRENDS IN PHARMACOLOGICAL SCIENCES, VOL 14, PG 174-178, 1993) [J].
AUDIBERT, FM ;
LISE, LD .
IMMUNOLOGY TODAY, 1993, 14 (06) :281-284
[4]   Regional specialization in the mucosal immune system: primed cells do not always home along the same track [J].
Brandtzaeg, P ;
Farstad, IN ;
Haraldsen, G .
IMMUNOLOGY TODAY, 1999, 20 (06) :267-277
[5]   IMMUNE-RESPONSES AND PROTECTION AGAINST BORDETELLA-PERTUSSIS INFECTION AFTER INTRANASAL IMMUNIZATION OF MICE WITH FILAMENTOUS HEMAGGLUTININ IN SOLUTION OR INCORPORATED IN BIODEGRADABLE MICROPARTICLES [J].
CAHILL, ES ;
OHAGAN, DT ;
ILLUM, L ;
BARNARD, A ;
MILLS, KHG ;
REDHEAD, K .
VACCINE, 1995, 13 (05) :455-462
[6]   Recent advances in mucosal vaccine development [J].
Chen, HM .
JOURNAL OF CONTROLLED RELEASE, 2000, 67 (2-3) :117-128
[7]   Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines [J].
Coombes, AGA ;
Major, D ;
Wood, JM ;
Hockley, DJ ;
Minor, PD ;
Davis, SS .
BIOMATERIALS, 1998, 19 (11-12) :1073-1081
[8]   Biodegradable lamellar particles of poly(lactide) induce sustained immune responses to a single dose of adsorbed protein [J].
Coombes, AGA ;
Lavelle, EC ;
Davis, SS .
VACCINE, 1999, 17 (19) :2410-2422
[9]  
COOMBES AGA, Patent No. 9702810
[10]  
Cooper P.D., 1994, STRATEGIES VACCINE D, P125